Canaccord Genuity Group Lowers TELA Bio (NASDAQ:TELA) Price Target to $2.00

TELA Bio (NASDAQ:TELA) had its price objective dropped by investment analysts at Canaccord Genuity Group from $4.00 to $2.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 168.06% from the company’s previous close.

Several other equities analysts also recently issued reports on TELA. Lake Street Capital reissued a “buy” rating on shares of TELA Bio in a research note on Monday, December 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TELA Bio in a research note on Thursday, January 22nd. Finally, Loop Capital set a $3.00 price target on TELA Bio in a report on Monday, December 1st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, TELA Bio currently has a consensus rating of “Hold” and a consensus price target of $2.60.

TELA Bio Trading Up 8.1%

Shares of TELA stock opened at $0.75 on Wednesday. The firm has a 50-day moving average price of $0.84 and a 200 day moving average price of $1.14. TELA Bio has a twelve month low of $0.62 and a twelve month high of $2.20. The company has a market capitalization of $30.10 million, a price-to-earnings ratio of -0.90 and a beta of 0.88. The company has a current ratio of 3.30, a quick ratio of 2.62 and a debt-to-equity ratio of 26.65.

TELA Bio (NASDAQ:TELA) last released its quarterly earnings results on Tuesday, March 24th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. The company had revenue of $20.87 million for the quarter, compared to analysts’ expectations of $21.04 million. TELA Bio had a negative net margin of 48.37% and a negative return on equity of 396.31%. Research analysts forecast that TELA Bio will post -1.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of TELA. Essex Woodlands Management Inc. boosted its position in shares of TELA Bio by 87.7% in the fourth quarter. Essex Woodlands Management Inc. now owns 7,714,709 shares of the company’s stock worth $9,103,000 after acquiring an additional 3,604,000 shares during the last quarter. Perkins Capital Management Inc. grew its holdings in TELA Bio by 67.6% in the fourth quarter. Perkins Capital Management Inc. now owns 1,397,418 shares of the company’s stock valued at $1,649,000 after purchasing an additional 563,490 shares during the period. HBK Sorce Advisory LLC acquired a new position in TELA Bio during the third quarter worth approximately $154,000. Embree Financial Group increased its position in TELA Bio by 695.1% during the fourth quarter. Embree Financial Group now owns 111,318 shares of the company’s stock worth $131,000 after purchasing an additional 97,318 shares during the last quarter. Finally, WealthTrust Axiom LLC raised its stake in TELA Bio by 39.1% during the fourth quarter. WealthTrust Axiom LLC now owns 322,588 shares of the company’s stock worth $381,000 after purchasing an additional 90,650 shares during the period. Institutional investors and hedge funds own 94.35% of the company’s stock.

TELA Bio News Roundup

Here are the key news stories impacting TELA Bio this week:

• Positive Sentiment: Management said Q4 produced record quarterly sales and double‑digit revenue growth while executing a “meaningful strategic change” and rebuilding the U.S. commercial organization — a sign of improving commercial traction. TELA Bio Q4 Earnings Call Highlights
• Positive Sentiment: Company set an operational target of at least 8% revenue growth for 2026, which frames upside if the commercial rebuild drives continued top‑line momentum. Tela Bio targets at least 8% revenue growth in 2026
• Neutral Sentiment: Q4 results beat EPS consensus by $0.02 (reported -$0.16 vs. -$0.18) but the company remains unprofitable, leaving near‑term earnings clarity mixed. TELA Bio (TELA) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: The formal fourth‑quarter and full‑year 2025 financial results release provides the detailed metrics investors will use to model 2026 cash burn and growth tradeoffs. TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Revenue narrowly missed analyst estimates ($20.87M vs. $21.04M), and the company continues to show negative margins and heavy losses — factors that pressure valuation for a small‑cap medical device name. TELA Bio, Inc. Q4 2025 Earnings Call Summary
• Negative Sentiment: Multiple analysts trimmed forecasts and lowered price targets after the release (Canaccord, Piper Sandler, Lake Street among others), signaling reduced near‑term expectations and adding selling pressure. TELA Bio Analysts Cut Their Forecasts After Q4 Results Price Target Lowered to $2.00 at Canaccord

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.